Recursion Pharmaceuticals (RXRX) has grabbed attention following the announcement of its merger with Exscientia, as well as updates on late-stage trial milestones and new regulatory clearances for ...
Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results